Search clinical trials for: Letermovir

Total 39 results

University of California, Irvine
Eurofins Viracor

Not yet recruiting

Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla

CMV | Allogeneic Stem Cell Transplantation

United States
Ruijin Hospital

Not yet recruiting

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Hematologic Malignancy
Anhui Provincial Hospital

Recruiting

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Cytomegalovirus Infection Reactivation

China
University of Wisconsin, Madison
Merck Sharp & Dohme LLC

Not yet recruiting

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Kidney Transplant Infection | Cytomegalovirus Infections | Pancreas Transplant

United States
Hospital do Rim e Hipertensão

Not yet recruiting

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

CMV Infection
Foundation IRCCS San Matteo Hospital
Ministero della Salute, Italy

Recruiting

HCMV Breakthrough Infections During Letermovir Prophylaxis (CMVbreak)

Cytomegalovirus Infections | Hematopoietic Stem Cell Transplantation | Cytomegalovirus Viremia

Italy
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections (LUCY-1)

Cytomegalovirus Infection

France
Cao Weijie

Recruiting

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Letemovir for the Prevention of CMV Infection After Allo-HSCT

China
Grupo Espanol de trasplantes hematopoyeticos y...

Not yet recruiting

Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers

CMV
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
University of Pennsylvania
Merck Sharp & Dohme LLC

Recruiting

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Cytomegalovirus Infections | Transplant-Related Disorder

United States
Maimónides Biomedical Research Institute of Córdoba
MERCK SHARP & DOHME DE ESPAÑA S.A.

Not yet recruiting

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. (LETERCOR)

Infections, Cytomegalovirus

Spain
The First Affiliated Hospital of Soochow University

Recruiting

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Hematopoietic Stem Cell Transplantation | CMV Infection

China
Virginia Commonwealth University
Merck Sharp & Dohme LLC

Recruiting

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip

CMV | Kidney Transplant; Complications

United States
Rabin Medical Center

Not yet recruiting

Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

CMV | Graft-versus-host-disease
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
The First Affiliated Hospital of Soochow University

Recruiting

Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China

Hematopoietic Stem Cell Transplantation | CMV Infection

China
Children's Oncology Group

Recruiting

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Tufts Medical Center

Recruiting

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Neutropenia | Cytomegalovirus Infections | Infection in Solid Organ Transplant Recipients | Antiviral Toxicity

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir (CYMEVAL3-step2)

Pregnant Women | CMV Infected Fetuses

France
University Medical Centre Ljubljana

Recruiting

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients (CYPHER-TXPilot)

CMV Viremia

Slovenia
Jean-Pierre Routy

Recruiting

Letermovir in ART-treated HIV-infected Persons (Letermovir)

People Living With HIV

Canada
Fernanda P Silveira, MD, MS
Merck Sharp & Dohme LLC

Recruiting

Letermovir for CMV Prevention After Lung Transplantation

CMV | Lung Transplant

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

CMV | CMV Infection | Hematopoietic Cell Transplant

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Sezary Syndrome | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | T-Cell Prolymphocytic Leukemia | B-Cell Prolymphocytic Leukemia

United States
Merck Sharp & Dohme LLC

Completed

A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

Cytomegalovirus Infection

China
Merck Sharp & Dohme LLC

Completed

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

Cytomegalovirus Infection | Cytomegalovirus Disease

Japan
Tufts Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Letermovir Use in Heart Transplant Recipients

Neutropenia | Cytomegalovirus Infections | Cytomegalovirus Disease | Heart Transplant Infection | Antiviral Toxicity

United States
Merck Sharp & Dohme LLC

Completed

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Cytomegalovirus (CMV) Infection

United States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
National Institute of Allergy and Infectious Diseases...
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. (ELICIT)

HIV Infections | Cytomegalovirus | CMV

United States
Peking University People's Hospital

Enrolling by invitation

Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Hematopoietic Stem Cell Transplantation | CMV Infection

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia... and other conditions

United States
Merck Sharp & Dohme LLC

Completed

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

CMV Disease

United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, France, Germany, Hungary, Italy, Mexico, New Zealand, Poland, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Cytomegalovirus Infection

United States, France, Germany, Italy, Japan, United Kingdom
Amy C. Sherman, MD
Merck Sharp & Dohme LLC

Completed

Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

Cytomegalovirus Infections

United States
Assistance Publique - Hôpitaux de Paris

Completed

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1) (CYMEVAL3-STEP1)

Pregnant Women Undergoing TOP | TOP - Failed Attempted Termination of Pregnancy

France
Merck Sharp & Dohme LLC

Completed

Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

Prevention of CMV Infection or Disease
AiCuris Anti-infective Cures AG
Quintiles, Inc.

Completed

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

HCMV Reactivation or HCMV End-Organ Disease

United States, Germany

Search clinical trials for: Letermovir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations